Latest Financial Health News

Decidr AI Industries reported an 82% revenue jump in its AI platform during Q4 FY25, launched AI Mentors with The Growth Faculty, and divested its 13Seeds business to sharpen focus on AI innovation.

Osteopore Limited has posted a record AUD 835K revenue in Q2 CY25, driven by strong APAC sales and new European market access following EU MDR clearance. The company also advances clinical trials and refreshes key distribution channels.

FlexiRoam Limited has achieved profitability in Q4 FY25, marking a significant turnaround with a positive EBITDA and net profit. Founder Jefrey Ong is appointed permanent CEO to steer the company’s next growth phase.

Vection Technologies capped FY25 with its highest monthly order intake ever, driven by defence and AI/XR contracts, while posting positive pro-forma cash flow despite payment timing issues.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Ardiden Limited advances exploration at its Pickle Lake Gold Project in Northwest Ontario, focusing on high-potential prospects while maintaining a robust financial position with A$11.4 million in cash and no debt.

Openn Negotiation Ltd has reported a remarkable financial turnaround in its half-year results to December 2024, shifting from a significant loss to a modest profit while divesting key subsidiaries.

Orpheus Uranium Limited reported a net cash outflow from operations and investing in the June quarter but strengthened its cash position through financing activities, extending its funding runway to over seven quarters.

Magnis Energy Technologies progresses detailed engineering on its Nachu Graphite Project and moves to fast track US anode material production, while navigating ASX suspension and IM3NY bankruptcy fallout.

CurveBeam AI reported a solid 18% increase in purchase orders for FY25, alongside record cash receipts and positive operational cash flow in Q4. The company is also advancing a significant vendor financing facility to support growth in key markets.

NGX Limited progresses its Malingunde graphite project with technical studies and stakeholder engagement, while uranium exploration permits advance in Namibia. The company stands to benefit from new US anti-dumping tariffs on Chinese graphite imports.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.